MobileODT
MobileODT develops portable, AI-based optical detection devices for cervical cancer screening, targeting healthcare providers and global health programs serving women in underserved settings. The company has been acquired by Liger Medical and operates as a brand within Liger Medical's women's healthcare device portfolio.
- Company typePrivate
- Founded2012
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What MobileODT does
MobileODT is a health-tech company founded in 2012 and headquartered in Tel Aviv, Israel, that develops portable medical devices for cervical cancer screening and pre-cancerous lesion detection. Its core product is a portable, easy-to-use cervical cancer screening device built on mobile optical detection technology, designed to bring point-of-care screening to settings where traditional colposcopy infrastructure is unavailable. The company targets the women's health / cervical cancer screening vertical, with a value proposition centered on accessibility, portability, and cost-effectiveness for underserved and resource-limited healthcare environments.
The company has raised approximately $14.1M across multiple funding rounds from 2012 through 2020, with OrbiMed as a repeat lead investor and participation from mission-aligned funds such as Laerdal Million Lives Fund, Tara Health Foundation, Tristel, MedTech Innovator, and Vodafone Americas Foundation. The company is led by CEO Leon A. Boston and operates with a small team of 11-50 employees. MobileODT has been acquired by Liger Medical, an altruistic organization focused on cost-effective women's healthcare devices, and now operates as a brand/subsidiary within Liger Medical's portfolio rather than as an independent entity.
MobileODT's business model historically centered on selling or distributing portable cervical cancer screening hardware and related consumables/services to healthcare providers, NGOs, and public health programs. Pricing details are not publicly disclosed. The product is positioned as a differentiated, miniaturized alternative to traditional colposcopy, with strategic alignment to global health cervical cancer screening initiatives.
MobileODT firmographics
Firmographics- Name
- MobileODT
- Website
- http://www.mobileodt.com/
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- MobileODT develops portable, AI-based optical detection devices for cervical cancer screening, targeting healthcare providers and global health programs serving women in underserved settings. The company has been acquired by Liger Medical and operates as a brand within Liger Medical's women's healthcare device portfolio.
- Ownership category
- akta.pro rank
MobileODT industry classification
Industry- Product category
- Cervical Cancer Screening Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Portable, Mobile & Point-of-Care Imaging Systems (HLAHABAL)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where MobileODT is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Markets served
MobileODT business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
MobileODT product offering
Product offeringCore offering
MobileODT develops and sells portable, AI-enabled medical devices for the screening and detection of pre-cervical cancer in women. The product line consists of compact optical imaging hardware combined with AI-based image analysis software, enabling healthcare providers to perform point-of-care cervical cancer screening in clinics, outreach programs, and underserved settings.
Differentiator
Problem solved
Functional benefit
Products and services
- Liger Medical Device Portfolio (MobileODT cervical cancer screening devices)
Companies that use MobileODT
Customer profileSegments1 record
Ideal customer profiles1 record
MobileODT technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
MobileODT partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Liger Medicalflagship
Recent moves3 records
Expansion highlights3 records
MobileODT competitors and assessment
Company assessmentBroad incumbents
- Hologic: Hologic is the dominant women's health diagnostics incumbent with ThinPrep cytology and Panther HPV testing platforms. It is the established standard-of-care cervical cancer screening vendor that any portable alternative must displace or complement.
- Becton, Dickinson and Company (BD): BD's Onclarity HPV assay and women's health diagnostics portfolio compete directly for cervical screening workloads. BD's scale, regulatory reach, and channel relationships make it a primary competitive benchmark.
- Roche Diagnostics: Roche's cobas HPV test is a flagship cervical cancer molecular diagnostic deployed globally. As a leading diagnostics platform, it defines the laboratory-based workflow that MobileODT's point-of-care device targets as an alternative or complement.
- CooperSurgical: CooperSurgical is a leading women's health medical device company spanning ART, obstetrics, and cervical screening/colposcopy products. It is a broad incumbent competing across the women's health device landscape MobileODT targets.
- Revvity (formerly PerkinElmer): Revvity provides clinical diagnostics and screening assays, including in oncology and women's health. As a broad diagnostics incumbent, it competes for the same cervical and women's health screening budgets as MobileODT.
Direct peers
- QIAGEN: QIAGEN provides digene HC2 and methylation-based cervical cancer screening assays (e.g., QIAsure). It directly competes in cervical diagnostics and is commonly co-evaluated alongside portable visual screening approaches.
- TruScreen: TruScreen is an emerging cervical cancer screening device using real-time opto-electrical tissue analysis at the point of care. It is one of the closest direct peers to MobileODT's portable visual AI screening offering.
- DYSIS Medical: DYSIS Medical builds DYSIS colposcopes with computer-aided mapping for cervical examination. It competes head-to-head in the portable colposcopy/visual screening segment that MobileODT addresses.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
MobileODT social profiles
Digital presenceMobileODT financial estimates
Financial estimateRevenue estimate
Valuation estimate
MobileODT leadership team
Management profileNumber of profiles
Profiles1 record
MobileODT funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MobileODT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MobileODT
What does MobileODT do?
MobileODT develops and sells portable, AI-enabled medical devices for the screening and detection of pre-cervical cancer in women. The product line consists of compact optical imaging hardware combined with AI-based image analysis software, enabling healthcare providers to perform point-of-care cervical cancer screening in clinics, outreach programs, and underserved settings.
Is MobileODT a public or private company?
MobileODT is a private company. It is classified as corporate owned and is currently acquired.
When was MobileODT founded?
MobileODT was founded in 2012. It employs 11 to 50 people.
Where is MobileODT based?
MobileODT is headquartered in Tel Aviv, Israel, in the Middle East region.
Who are MobileODT's main competitors?
Broad incumbents on record are Hologic, Becton, Dickinson and Company (BD), Roche Diagnostics, CooperSurgical and Revvity (formerly PerkinElmer). Direct peers are QIAGEN, TruScreen and DYSIS Medical.
Does MobileODT have an API?
No public API is recorded for MobileODT.
What industry is MobileODT in?
MobileODT's product category is Cervical Cancer Screening Medical Devices. Its primary akta.pro industry code is HLAHABAL, Portable, Mobile & Point-of-Care Imaging Systems, with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3841.